EUVIMEDEUVIMED entdecken
Crossref

Sustained Alleviation of Autoimmunity by Activating α2B-adrenergic Receptors

Veena Viswanath, Shruti Mistry, Sara Cabrera-Ghayouri, Ronika Leang, Don Frail iD, John Donello, Daniel Gil

The Journal of Immunology · 15.08.2024 · 213 (4) · 435-441

DOI: 10.4049/jimmunol.2300893 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Immunology, online erschienen am 28.06.2024. Verfasst von Veena Viswanath und 6 weiteren Autor:innen. Beteiligte Einrichtung: Ophthalmology Discovery Research, AbbVie Inc., Irvine, CA. Hauptthemen laut MEDLINE: Receptors, Adrenergic, alpha-2, Autoimmunity, Adrenergic alpha-2 Receptor Agonists. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Catecholamines binding to α- and β-adrenergic receptors on immune cells have recently been shown to play an important role in regulating immune responses. Although α2-adrenergic receptors are known to modulate the immune response in different ways, the therapeutic exploration of their utility has been limited by the lack of agonists selective for the three α2-adrenergic subtypes. We report in this study the identification of the agonist AGN-762, which activates α2B- and α2C-adrenergic subtypes, but not the α2A subtype. We show that AGN-762 reduced clinical disease in an experimental autoimmune encephalitis model of autoimmune disease via direct or indirect effects on T regulatory cells. The activity of AGN-762 was abrogated by depletion of T regulatory cells, which express the α2B-adrenergic receptor. Furthermore, a drug-induced shift to an anti-inflammatory phenotype was demonstrated in immune cells in the spleen of drug-treated experimental autoimmune encephalitis mice. AGN-762 does not display sedative and cardiovascular side effects associated with α2A subtype agonists. Immune modulation by selective α2-adrenergic agonists represents a novel, to our knowledge, approach for treating autoimmune disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Adrenergic, alpha-2AutoimmunityAdrenergic alpha-2 Receptor AgonistsAnimalsMiceMice, Inbred C57BLT-Lymphocytes, RegulatoryEncephalomyelitis, Autoimmune, ExperimentalHumansFemaleDisease Models, Animal

Substanzen

Receptors, Adrenergic, alpha-2Adrenergic alpha-2 Receptor Agonists

Autor:innen und Institutionen

  • Ophthalmology Discovery Research, AbbVie Inc., Irvine, CA.
  • Alceptor Therapeutics, Newport Beach, CA.

ORCID-Profile: Don Frail

Zitieren

APA

Viswanath, V., Mistry, S., Cabrera-Ghayouri, S., Leang, R., Frail, D., Donello, J., & Gil, D. (2024). Sustained Alleviation of Autoimmunity by Activating α2B-adrenergic Receptors. The Journal of Immunology, 213(4), 435-441. https://doi.org/10.4049/jimmunol.2300893

Vancouver

Viswanath V, Mistry S, Cabrera-Ghayouri S, Leang R, Frail D, Donello J, et al. Sustained Alleviation of Autoimmunity by Activating α2B-adrenergic Receptors. The Journal of Immunology. 2024;213(4):435-441. doi:10.4049/jimmunol.2300893

BibTeX
@article{Viswanath2024,
  author = {Viswanath, Veena and Mistry, Shruti and Cabrera-Ghayouri, Sara and Leang, Ronika and Frail, Don and Donello, John and Gil, Daniel},
  title = {Sustained Alleviation of Autoimmunity by Activating α2B-adrenergic Receptors},
  journal = {The Journal of Immunology},
  year = {2024},
  volume = {213},
  number = {4},
  pages = {435--441},
  doi = {10.4049/jimmunol.2300893}
}
Kostenlos starten →